Your browser version may not work well with NCBI's Web applications. More information here...
1: Am J Hematol. 2008 Mar;83(3):233-6.Click here to read Links

Pharmacogenetics of morphine: Potential implications in sickle cell disease.

Darbari DS, Minniti CP, Rana S, van den Anker J.

Center for Cancer and Blood Disorders, Children's National Medical Center, Washington, DC 20010, USA. ddarbari@cnmc.org

Morphine is frequently used to treat painful episodes associated with sickle cell disease (SCD) but may fail to provide adequate analgesia in many patients. This concise review focuses on unique disease related changes in physiologic variables associated with SCD that impacts pharmacokinetics and pharmacodynamics of morphine and may contribute to the variability in analgesia. Emerging evidence suggests that the allelic variants in the genes involving the opioid (UGT2B7, OPRM1, and ABCB1 genes) and nonopioid system (COMT gene) can alter the efficacy of morphine. (c) 2007 Wiley-Liss, Inc.

PMID: 17722074 [PubMed - indexed for MEDLINE]